A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...